An archive photo
MINSK, 14 October (BelTA) – The Belarusian pharmaceutical industry is building presence on new markets, Director General of the Belpharmprom Holding Company Igor Mitrofanov told journalists, BelTA reports.
“As part of our export diversification strategy, we seek to establish and expand our presence in Asia, Latin America, and Africa. Negotiations are underway with Mozambique, Uganda, and Libya. We are also trying to penetrate the markets of Zimbabwe, Kenya, and Equatorial Guinea,” said Igor Mitrofanov.
According to him, the CIS remains the key market for Belarusian medicines. The export to this region makes up about 90% of all exports.
All in all, Belarusian pharmaceutical products have a fairly broad geographical representation. They were shipped to 24 countries of the world, including nine CIS member states and 15 far-arc countries. Pharmaceutical companies of all forms of ownership sell their products abroad.
“In other words, we have joined efforts to build and increase our presence in the neighboring and distant arc markets,” noted Igor Mitrofanov.
“As part of our export diversification strategy, we seek to establish and expand our presence in Asia, Latin America, and Africa. Negotiations are underway with Mozambique, Uganda, and Libya. We are also trying to penetrate the markets of Zimbabwe, Kenya, and Equatorial Guinea,” said Igor Mitrofanov.
According to him, the CIS remains the key market for Belarusian medicines. The export to this region makes up about 90% of all exports.
All in all, Belarusian pharmaceutical products have a fairly broad geographical representation. They were shipped to 24 countries of the world, including nine CIS member states and 15 far-arc countries. Pharmaceutical companies of all forms of ownership sell their products abroad.
“In other words, we have joined efforts to build and increase our presence in the neighboring and distant arc markets,” noted Igor Mitrofanov.
Follow us on:
